Article
A third interim safety analysis of an ongoing multicenter phase II trial of NX-1207, for the treatment of BPH, has revealed no serious side effects, according to Nymox Pharmaceutical Corp., the drug's manufacturer.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.